Search company, investor...

The Genetics Company

Stage

Other Investors | Alive

About The Genetics Company

The Genetics Company has developed and is selling an Alzheimer antibody based diagnostic tool kit for research and clinical purposes. In addition, it is exploiting expertise and preclinical assets achieved in the the WNT-pathway relating to cancer.

Headquarters Location

Switzerland

Missing: The Genetics Company's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: The Genetics Company's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing The Genetics Company

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

The Genetics Company is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

The Genetics Company Patents

The Genetics Company has filed 1 patent.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/23/2019

8/23/2022

Molecular biology, Biotechnology, Small nuclear RNA, DNA, Genetics

Grant

Application Date

7/23/2019

Grant Date

8/23/2022

Title

Related Topics

Molecular biology, Biotechnology, Small nuclear RNA, DNA, Genetics

Status

Grant

Latest The Genetics Company News

DTC Genetics Company Nucleus Genomics Raises $18 Million in Funding in One Year

Jul 14, 2022

Seed+ funding round led by Seven Seven Six nets $14 million July 14, 2022 10:27 AM Eastern Daylight Time NEW YORK--( BUSINESS WIRE )-- Nucleus Genomics , a next-generation consumer genetic testing and analysis company, has raised $14 million in a new funding round led by Alexis Ohanian's Seven Seven Six. The NYC-based company, founded by Kian Sadeghi, is building a DTC genetic testing platform that provides innovative genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS). The company also believes in maximal data ownership and liberty by providing its users total autonomy over their genetic data. Ohanian joins a lineup of investors across technology, healthcare, and media, including Founders Fund, Adrian Aoun (CEO, Forward Health), Brent Saunders (former CEO, Allergan), Patrick Hsu (Bioengineering Professor, UC Berkeley), Hugo Barra (CEO, Detect), Austen Allred (CEO, Bloom Institute of Technology), Packy McCormick (Founder, Not Boring), Shrug Capital, Alexandra Botez (influencer), Anthony Pompliano, and many others. The additional funding, along with the company’s initial seed financing raised in 2021 , will help Nucleus bolster its scientific and engineering team. They are continuing to set up the computational and physical infrastructure required to analyze whole-genome sequencing (WGS) data at scale, customize disease and trait reports, and send genetic testing kits to users. Nucleus provides WGS genetic testing kits for users to receive rare variant analysis and polygenic scores across a wide variety of diseases and traits — ranging from breast cancer risk to longevity disposition. Individuals who have done DTC microarray genetic testing from companies such as 23andMe can upload their genotyped DNA on the Nucleus platform to receive a subset of the possible genetic analyses, centering around polygenic scores. These scores are calculated by combining the effects of hundreds, thousands, or even millions of DNA letters that vary from one individual to another. A big part of Nucleus’ mission is to ensure that the user’s overall experience from the reports is personalized by combining genetic and non-genetic data. "We want people to see all their data — their whole-genome sequence, blood tests, doctors’ reports, sleep cycle, running duration — their entire health story in one place," said Lasse Folkersen, Ph.D., Nucleus' Chief Scientific Officer. "But most importantly, they will see how their daily life decisions, combined with their genetics, influence their traits and risk for disease. That's where our algorithms and scientific expertise play a critical role." Nucleus is acutely aware of the lack of diversity in genomic datasets. The company is looking to help gradually fix this issue by making their reports accessible, informative and inclusive. “Nucleus is reimagining the DTC genetic analysis experience for people of all ages, across all places,” said Caio Hachem, Nucleus’ Chief Operations Officer. “Our team, which consists of people across the globe, reflects the diversity we want to see in our user base.” "The promise of personalizing the healthcare experience was made decades ago,” Sadeghi added. “Nucleus is bringing that promise to fruition, starting with consumer genetic testing.” Click here for more information. About Nucleus Genomics Nucleus is redefining DTC genetic testing. By combining polygenic scores with traditional rare variant DNA analysis, the company provides comprehensive assessments of genetic disposition across a myriad of diseases and traits. Nucleus’ mission is to empower people to take agency over their health so no one dies from preventable disease -- that’s why the company is building a platform based on cutting-edge science, where everyone has their genome in their pocket, complete clarity on their risks, and are empowered by personalized health measures. Nucleus is also bridging the gap between people, doctors, and scientists to help discoveries, therapies, and cures find their way to people faster. Learn more at mynucleus.com . Contacts

The Genetics Company Frequently Asked Questions (FAQ)

  • What is The Genetics Company's latest funding round?

    The Genetics Company's latest funding round is Other Investors.

  • Who are the investors of The Genetics Company?

    Investors of The Genetics Company include Novartis Venture Funds.

  • Who are The Genetics Company's competitors?

    Competitors of The Genetics Company include Linkage Biosciences, Aureon Laboratories, Nodality, Avid Radiopharmaceuticals, Vitrimark and 7 more.

Compare The Genetics Company to Competitors

L
Litholink

Litholink offers metabolic evaluations for kidney stone formers.

H
Hematotypes

Hematotypes is a medical technology company dedicated to improving the way cancers of the blood, lymphoma, and leukemia are identified.

Canary Foundation Logo
Canary Foundation

Canary Foundation was founded in 2004 by Don Listwin, a successful high-technology executive who lost his mother to misdiagnosed ovarian cancer. Don discovered that although almost $10 billion is spent annually on cancer research in the United States, the vast majority is allocated to developing new cancer treatments and caring for patients. Surprisingly, little funding is available to researchers investigating new ways to detect cancer it at its earliest, curable stages. Don made a commitment to use his time, energy, expertise, enthusiasm, professional network, and his own family foundation's resources to build a non-profit organization that will succeed at the creation of an early warning system for cancer. His ongoing passion is to build the foundation that connects the very best cancer researchers with entrepreneurs and venture capitalists so that their breakthroughs will have chances of saving lives. Don recruited Dr.Lee Hartwell, 2001 Nobel Laureate, to help form the Canary Science Team from the most outstanding, scientifically researchers available from various disciplines. Science team members come from widely different fields and institutions to meet on a regular basis where they share ideas and breakthroughs. Canary has devised a simple process to provide money and tools for team members to accomplish their stated goals at a rapid pace and with directly applicable results. Tools include software to share data, dedicated websites, project management support, quarterly collaboration meetings and project reviews. One of a decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers produced by cancer. Ovarian cancer was chosen as it is generally considered asymptomatic until late stage and has relatively low occurrence. Knowledge, techniques, and data gathered from the Ovarian Cancer Program are being leveraged to expand into other types of cancers (Pancreatic, Prostate and Lung). In addition to blood tests, the Science Team is working on advancing imaging techniques and agents for general body scanning technology using PET, Ultrasound and other imaging modalities for pinpointing the exact cancer location in order to eradicate it while it is still small and before it has spread. Canary hopes that by delivering on a effective test for early detection of cancer it will spur a dramatic increase of funds into the early detection field from the National Cancer Institute and the venture capital community so that products based on this research will arrive faster and save millions of lives per year.

C
Crescent Diagnostics

Crescent Diagnostics develops Osentia, a commercially available diagnostic test to identify an individual's risk of developing osteoporosis.

J
JJET

JJET is committed to the development, production, and sales of products in the field of electrophysiology; the products mainly include a three-dimensional cardiac mapping system, multi-channel physiological recorder, cardiac electrophysiological stimulator, cardiac radiofrequency ablation device, cold saline perfusion pump, cardiac electrophysiological mapping catheter, cardiac radiofrequency ablation catheter, nerve radiofrequency treatment instrument. The company was founded in 1991 and is based in Chengdu, China.

V
Vitrimark

Vitrimark is an imaging company that uses cryogenic transmission electron microscopy to identify structural biomarkers for the early detection of disease, and exploit their utility for integration in the drug development process. Biomarkers are observable characteristics of biological or clinical samples that indicate progression to disease, drug response or toxicity. The identification of biomarkers is expected to relieve the deepening productivity crisis in the pharmaceutical industry by lowering drug development costs. It will do this by allowing early and cost-effective go/no-go decisions, permitting patient stratification, helping in the analysis of clinical trials and finding niche markets for drugs under development, or drugs already commercialized. Vitrimark aims to discover structural biomarkers for prostate and breast cancer, type 2 diabetes and in the longer term, Alzheimer's disease. It will build a biomarker patent portfolio surrounding its technology and their applications and then license the utility of these biomarkers to clients (pharmaceutical companies) for use in their clinical drug development processes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.